We investigated the relationship between the prognostic importance of anatomic tumour burden and subtypes of breast cancer using data from the Korean Breast Cancer Registry Database. In HR+/HER2+ and HR−/HER2−tumours, an increase in T stage profoundly increased the hazard of death, while the presence of lymph node metastasis was more important in HR+/HER2+ and HR−/HER2+ tumours among 131,178 patients with stage I–III breast cancer. The patterns of increasing mortality risk and tumour growth (per centimetre) and metastatic nodes (per node) were examined in 67,038 patients with a tumour diameter ≤ 7 cm and < 8 metastatic nodes. HR+/HER2− and HR−/HER2− tumours showed a persistent increase in mortality risk with an increase in tumour diameter, while the effect was modest in HER2+ tumours. Conversely, an increased number of metastatic nodes was accompanied by a persistently increased risk in HR−/HER2+ tumours, while the effect was minimal for HR−/HER2− tumours with > 3 or 4 nodes. The interactions between the prognostic significance of anatomic tumour burden and subtypes were significant. The prognostic relevance of the anatomic tumour burden was non-linear and highly dependent on the subtypes of breast cancer.

我们使用来自韩国乳腺癌登记数据库的数据研究了解剖肿瘤负荷的预后重要性与乳腺癌亚型之间的关系。在 HR+/HER2+ 和 HR-/HER2- 肿瘤中，T 分期的增加显着增加了死亡风险，而在 131,178 名 I 期患者中，淋巴结转移在 HR+/HER2+ 和 HR-/HER2+ 肿瘤中更为重要–III 乳腺癌。在 67,038 名肿瘤直径 ≤ 7 cm 和 < 8 个转移淋巴结的患者中检查了死亡风险和肿瘤生长（每厘米）和转移淋巴结（每淋巴结）的增加模式。HR+/HER2- 和 HR-/HER2- 肿瘤显示死亡率风险随着肿瘤直径的增加而持续增加，而对 HER2+ 肿瘤的影响不大。反过来，转移性淋巴结数量的增加伴随着 HR-/HER2+ 肿瘤风险的持续增加，而对于具有 > 3 或 4 个淋巴结的 HR-/HER2- 肿瘤影响最小。解剖肿瘤负荷的预后意义与亚型之间的相互作用是显着的。解剖肿瘤负荷的预后相关性是非线性的，并且高度依赖于乳腺癌的亚型。